• CRISPR Therapeutics recently highlighted its expanding gene-editing pipeline, including cardiovascular and metabolic programs such as CTX310 and CTX320, and past participation by senior management in the 25th Annual Needham Virtual Healthcare Conference via a webcast.
• The focus on one-time gene-editing approaches for conditions linked to elevated LDL, triglycerides, and lipoprotein(a) underlines how CRISPR-based therapies may reshape treatment options for high‑risk patients.
• We will now examine how CRISPR Therapeutics’ focus on CTX310’s one-time ANGPTL3 gene-editing approach influences its broader investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

What Is CRISPR Therapeutics' Investment Narrative?

To own CRISPR Therapeutics, you really have to believe that its CRISPR/Cas9 platform and one-time in vivo gene-editing approach can translate a broad early pipeline into commercially relevant therapies, despite very limited current revenue and steep losses of US$581.6 million in 2025. The recent Needham Virtual Healthcare Conference appearance and discussion of CTX310 and CTX320 do not materially change the near term catalysts, which still center on additional CTX310 Phase 1 data later in 2025, early signals from CTX320, and progress across its liver and cell therapy programs. Where the news does matter is in reinforcing management’s narrative that cardiovascular and metabolic indications sit at the core of the story, sharpening execution risk around these assets at a time when the company is burning significant cash and remains far from profitability.

However, investors should also weigh how ongoing losses and future funding needs might affect their thesis. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Twelve Simply Wall St Community fair values span roughly US$20 to US$189, underscoring how far apart individual views sit, especially given CRISPR Therapeutics’ heavy losses and dependence on successful CTX310 data to support its gene-editing ambitions.

Explore 12 other fair value estimates on CRISPR Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 62 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.